LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Chi, K.N.N., Castro, E., Attard, G., Smith, M.R., Sandhu, S.K., Efstathiou, E., Roubaud, G., Small, E.J.J., Gomes, A.J.P.D.S., Rathkopf, D., Saad, M., Gurney, H.P., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., Olmos, D.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
Attard, G., Sandhu, S.K., Rathkopf, D., Castro, E., Saad, M., Smith, M.R., Small, E.J.J., Olmos, D., Gomes, A.J.P.D.S., Roubaud, G., Zurawski, B., Efstathiou, E., Wu, D., Diorio, B., Urtishak, K., Singh, U., Xu, Y., Lopez-Gitlitz, A., del Corral, A., Chi, K.N.N.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article